Percutaneous tumor ablation: Increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model

被引:100
作者
Goldberg, SN
Girnan, GD
Lukyanov, AN
Ahmed, M
Monsky, WL
Gazelle, GS
Huertas, JC
Stuart, KE
Jacobs, T
Torchillin, VP
Halpern, EF
Kruskal, JB
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiol, Boston, MA 02215 USA
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med Oncol, Boston, MA 02215 USA
[3] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA
[4] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
[5] Northeastern Univ, Bouve Coll Hlth Sci, Dept Pharmaceut Sci, Boston, MA 02115 USA
[6] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA
关键词
animals; breast neoplasms; therapy; chemotherapy; hyperthermia; radiofrequency (RF) ablation;
D O I
10.1148/radiol.2223010861
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: To determine whether a combination of intravenous liposomal doxorubicin and radio-frequency (RF) ablation increases tumor destruction compared with RF alone in an animal tumor model. MATERIALS AND METHODS: R3230 mammary adenocarcinoma 1.4-1.8-cm-diameter nodules were implanted subcutaneously in 132 female Fischer rats. Initially, tumors were treated with (a) conventional, monopolar RF (mean, 250 mA +/- 25 [SD] at 70degreesC +/- 1 for 5 minutes) ablation alone, (b) RF ablation followed by intravenous administration of 1 mg of liposomal doxorubicin, (c) RF ablation followed by intravenous administration of 1 mg of empty liposomes, (d) RF ablation and direct intratumoral administration of liposomal doxorubicin, or (e) no treatment. Subsequently, the dose (0.06-2.00 mg) of liposomal doxorubicin, the timing of administration (3 days before to 3 days after RF ablation), and the time of pathologic examination (0-72 hours after treatment) were varied. RESULTS: Mean coagulation diameter for treated tumors follows: 6.7 mm +/- 0.6, RF ablation alone; 11.1 mm +/- 1.5, RF ablation and intravenous administration of empty liposomes (P < .05, compared with RF ablation alone); and 8.4 mm +/- 1.1, RF ablation with intratumoral administration of liposomal doxorubicin (P < .05, compared with RF ablation alone). Maximal increased mean coagulation diameter (13.1 mm 1.5) was observed with a combination of liposomal doxorubicin and RF ablation (P < .001, for all comparisons). The increased coagulation for combination therapy developed over 48 hours after therapy. Coagulation diameter did not vary with the doxorubicin concentration range and was not dependent on the timing of administration of liposomal doxorubicin from 3 days before to 24 hours after RF ablation. CONCLUSION: Intravenous administration of liposomal doxorubicin can improve RF ablation, since it increases coagulation diameter in solid tumors compared with RF ablation alone or a combination of RF ablation with administration of empty liposomes. (C) RSNA, 2002.
引用
收藏
页码:797 / 804
页数:8
相关论文
共 36 条
[11]  
Goldberg SN, 2000, CANCER, V88, P2452, DOI 10.1002/1097-0142(20000601)88:11<2452::AID-CNCR5>3.0.CO
[12]  
2-3
[13]   Percutaneous tumor ablation: Increased necrosis with combined radio-frequency ablation and intratumoral doxorubicin injection in a rat breast tumor model [J].
Goldberg, SN ;
Saldinger, PF ;
Gazelle, GS ;
Huertas, JC ;
Stuart, KE ;
Jacobs, T ;
Kruskal, JB .
RADIOLOGY, 2001, 220 (02) :420-427
[14]   Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer [J].
Gordon, AN ;
Granai, CO ;
Rose, PG ;
Hainsworth, J ;
Lopez, A ;
Weissman, C ;
Rosales, R ;
Sharpington, T .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3093-3100
[15]   Liver tumor ablation: Real-time monitoring with dynamic CT [J].
Hahn, PF ;
Gazelle, GS ;
Jiang, DY ;
Compton, CC ;
Goldberg, SN ;
Mueller, PR .
ACADEMIC RADIOLOGY, 1997, 4 (09) :634-638
[16]   Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment [J].
Hobbs, SK ;
Monsky, WL ;
Yuan, F ;
Roberts, WG ;
Griffith, L ;
Torchilin, VP ;
Jain, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) :4607-4612
[17]   Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study [J].
Hong, RL ;
Tseng, YL ;
Chang, FH .
ANNALS OF ONCOLOGY, 2000, 11 (03) :349-353
[18]  
HUANG SK, 1994, CANCER RES, V54, P2186
[19]  
Kokura S, 1997, CANCER RES, V57, P2200
[20]  
Kong G, 1999, INT J HYPERTHER, V15, P345, DOI 10.1080/026567399285558